Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 11:33 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 673–696 of 3,553 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Fluids Clear all

Conditions: Digestive System Disease
Interventions: Low-dose PvP001, Medium-dose PvP001, High-dose PvP001, Placebo; Drug
Lead sponsor: Danielle Kim Turgeon; Other
Eligibility: 18 Years to 64 Years
Enrollment: 43 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Atopic Dermatitis
Interventions: Tralokinumab, Placebo, Tdap vaccine, Meningococcal vaccine; Drug · Biological
Lead sponsor: LEO Pharma; Industry
Eligibility: 18 Years to 54 Years
Enrollment: 215 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 39
States / cities: Fort Smith, Arkansas • Bakersfield, California • Beverly Hills, California + 33 more

Conditions: Metastatic Malignant Neoplasm in the Adult Brain, Primary Brain Tumor
Interventions: Therapeutic Conventional Surgery, Biopsy, Eribulin Mesylate, Microdialysis, Pharmacological Study; Procedure · Drug · Other
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2024
U.S. locations: 1
States / cities: Duarte, California

Conditions: Neonatal Respiratory Distress
Interventions: Infasurf Aero; Combination Product
Lead sponsor: ONY; Industry
Eligibility: Up to 42 Weeks
U.S. locations: 5
States / cities: Jackson, Mississippi • Buffalo, New York • Greenville, North Carolina + 2 more

Conditions: MicroRNA in Endometrial Fluid
Interventions: Endometrial fluid aspiration; Procedure
Lead sponsor: Stanford University; Other
Eligibility: 21 Years to 45 Years · Female only
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Stanford, California

Conditions: Aspiration
Interventions: Sidelying, Upright; Other
Lead sponsor: Connecticut Children's Medical Center; Other
Eligibility: 38 Weeks to 56 Weeks
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Hartford, Connecticut

Conditions: Diabetes Mellitus, Type 2, Sleep Hygiene
Interventions: Diabetes Self-Management and Support (DSMES) and Sleep Hygiene Education and Support (SHES); Behavioral
Lead sponsor: University of Arkansas; Other
Eligibility: 18 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Fayetteville, Arkansas

Conditions: Lennox Gastaut Syndrome
Interventions: Carisbamate; Drug
Lead sponsor: SK Life Science, Inc.; Industry
Eligibility: 2 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 5
States / cities: Baltimore, Maryland • Lebanon, New Hampshire • Portland, Oregon + 2 more

Conditions: Sepsis, Emergency Medical Services, Quality Improvement, Shock, Septic, Fluid Therapy
Interventions: Incorporation of Rapid Fluid Infusion Device in Prehospital Suspected Sepsis Protocol, Conventional Prehospital Suspected Sepsis Protocol; Other
Lead sponsor: Orange Park Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Orange Park, Florida

Conditions: End Stage Renal Disease
Interventions: Triferic; Drug
Lead sponsor: Rockwell Medical Technologies, Inc.; Industry
Eligibility: Up to 17 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 9
States / cities: Birmingham, Alabama • Loma Linda, California • Stanford, California + 6 more

Conditions: Hypothermia
Interventions: Dynatherm Medical vitalHEAT Temperature Management System vH2, Bair Hugger™ (Arizant Healthcare, Eden Prairie, MN); Device
Lead sponsor: University of South Florida; Other
Eligibility: 18 Years to 80 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Liver
Interventions: Questionnaires; Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Colorectal Cancer Liver Metastases (CRLM), Metastatic Colorectal Carcinoma (mCRC)
Interventions: EXELION; Other
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Duarte, California

Conditions: Muscle Loss, Protein, Mobility, Pediatric ALL
Interventions: Protein dosage and rehabilitation team delivered exercise prescription; Other
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 1 Year to 17 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 2
States / cities: Baltimore, Maryland • Boston, Massachusetts

Conditions: Triple-negative Breast Cancer
Interventions: LAG525, PDR001, Carboplatin; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 2
States / cities: Chandler, Arizona • Fayetteville, Arkansas

Conditions: Urinary Tract Infections, Sepsis
Interventions: Gentamicin, Placebo; Drug · Other
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Glioblastoma Multiforme
Interventions: Dichloroacetate (DCA), Genotype; Drug · Genetic
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 80 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 2
States / cities: Baltimore, Maryland • Winston-Salem, North Carolina

Conditions: Bronchopulmonary Dysplasia, Hyponatremia on Diuretics
Interventions: Sodium supplementation, Fluid restriction; Procedure
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 4 Weeks to 6 Months
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Cancer, Depression, Anxiety
Interventions: Ketamine, Placebo; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 2
States / cities: Scottsdale, Arizona • Yuma, Arizona

Conditions: Specimens Are to be Collected From Subjects Who Are Having or Have Had a Fluid or Tissue Removed, a Biopsy or a Blood or Bone Marrow Draw
Interventions: Specimen Collection; Other
Lead sponsor: Sohail Rao; Other
Eligibility: Not listed
Enrollment: 1,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 2
States / cities: Edinburg, Texas

Conditions: Medulloblastoma, Childhood, Recurrent, Atypical Teratoid/Rhabdoid Tumor, Medulloblastoma Recurrent
Interventions: Modified Measles Virus, Modified Measles Virus Lumbar Puncture; Biological
Lead sponsor: Sabine Mueller, MD, PhD; Other
Eligibility: 12 Months to 39 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 8
States / cities: Los Angeles, California • San Francisco, California • Chicago, Illinois + 5 more

Conditions: Leukemia, Myelodysplastic Syndromes
Interventions: aldesleukin, filgrastim, natural killer cell (NK) therapy, cyclophosphamide, cyclosporine, fludarabine phosphate, methylprednisolone, mycophenolate mofetil, Umbilical Cord Blood Transplantation (UCBT), Total body irradiation (TBI); Biological · Drug · Procedure + 1 more
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: Up to 45 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Tonsillitis, Pain
Interventions: Codeine with acetaminophen, Tramadol suspension; Drug
Lead sponsor: Children's Hospitals and Clinics of Minnesota; Other
Eligibility: 4 Years to 15 Years
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Type 1 Diabetes Mellitus
Interventions: Humalog, Humulin-R, Recombinant human hyaluronidase PH20 (rHuPH20), Liquid meal; Drug · Other
Lead sponsor: Halozyme Therapeutics; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Chula Vista, California

Search by objective public record fields.

Gastric Gluten-Degradation Activity of PvP001

Vaccine Responses in Tralokinumab-Treated Atopic Dermatitis - ECZTRA 5 (ECZema TRAlokinumab Trial No. 5)

Neuropharmacokinetics of Eribulin Mesylate in Treating Patients With Primary or Metastatic Brain Tumors

Aerosolized Infasurf Treatment Protocol: Aerosolized Infasurf for Spontaneously Breathing Patients With Early RDS (AERO-03)

Transciptomic Modification Induced by miRNAs in Endometrial Fluid

The Effect of Body Position on Oropharyngeal Swallow Function in Infants

Diabetes Self-Management Education with Sleep Hygiene

Carisbamate Safety Study in Adult and Pediatric Subjects With Lennox-Gastaut Syndrome

Orange Park Out-of-Hospital Quality Improvement Study for Improving CMS Sepsis Core Measures

Triferic Pediatric Pharmacokinetic Protocol

Intraoperative Warming Comparison of Devices

Accelerated Recovery After MIS Hepatectomy (ARAMIS Hep) to Support Early Discharge for Patients Undergoing Minimally Invasive Liver Resection

Exosome-derived Extrahepatic Metastasis Detection By Liquid Biopsy In Colorectal Cancer Liver Metastases

PRotein Optimization With eXercise to Improve MUscle Mass and Functional outcomeS

A Study of Efficacy and Safety of LAG525 in Combination With Spartalizumab, or With Spartalizumab and Carboplatin, or With Carboplatin, in Patients With Advanced Triple-negative Breast Cancer

Use of Antibiotic Based Irrigation for Ureteroscopic Treatment of Urolithiasis

Trial of Dichloroacetate (DCA) in Glioblastoma Multiforme (GBM)

Management of Hyponatremia in Preterm Infants on Diuretics

Oral Ketamine in the Treatment of Depression and Anxiety in Patients With Cancer

B2RAD Translational Medicine Study

Modified Measles Virus (MV-NIS) for Children and Young Adults With Recurrent Medulloblastoma or Recurrent ATRT

Donor Umbilical Cord Blood Natural Killer Cells, Aldesleukin and Umbilical Cord Blood Transplant in Patients With Refractory Hematologic Cancers.

A Comparison of Postoperative Tramadol Versus Acetaminophen With Codeine in Children Undergoing Tonsillectomy

Phase II Pharmacokinetics Study of Humalog and Humulin-R With and Without rHuPH20 in Type 1 Diabetes Mellitus